MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529714 | Name: Sinitrodil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sinitrodil is a guanylate cyclase stimulant potentially for the treatment of myocardial ischaemia and angina

Chemical Structure

Sinitrodil
Sinitrodil
CAS#143248-63-9

Theoretical Analysis

MedKoo Cat#: 529714

Name: Sinitrodil

CAS#: 143248-63-9

Chemical Formula: C10H10N2O5

Exact Mass: 238.0590

Molecular Weight: 238.19

Elemental Analysis: C, 50.42; H, 4.23; N, 11.76; O, 33.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ITF-296; ITF296; ITF 296
IUPAC/Chemical Name
2-(4-oxo-2H-benzo[e][1,3]oxazin-3(4H)-yl)ethyl nitrate
InChi Key
POVFCWQCRHXYAB-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H10N2O5/c13-10-8-3-1-2-4-9(8)16-7-11(10)5-6-17-12(14)15/h1-4H,5-7H2
SMILES Code
O=C1N(CCO[N+]([O-])=O)COC2=CC=CC=C12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 238.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Minghetti P, Casiraghi A, Montanari L, Monzani MV. In vitro skin permeation of Sinitrodil, a member of a new class of nitrovasodilator drugs. Eur J Pharm Sci. 1999 Feb;7(3):231-6. PubMed PMID: 9845810. 2: Monzani MV, Coltro G, Sala A, Sardina M. Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci. 1999 Feb;7(3):179-84. PubMed PMID: 9845803. 3: Van Bortel LM, Spek JJ, Balkestein EJ, Sardina M, Struijker Boudier HA. Is it possible to develop drugs that act more selectively on large arteries? J Hypertens. 1999 May;17(5):701-5. PubMed PMID: 10403615. 4: Khattar RS, Senior R, Sardina M, Boyce M, Lahiri A. Safety, tolerability, and antiischaemic efficacy of ITF-296, a nitric oxide donor, in patients with chronic stable angina. J Cardiovasc Pharmacol. 1998 Aug;32(2):295-9. PubMed PMID: 9700993. 5: Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. Pharmacokinetic study in rats after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):230-8. PubMed PMID: 9725487. 6: Giachetti C, Bertolino M, Canali S, Lombardini E, Monzani MV, Sala A, Zanolo G. Pharmacokinetic study in dogs and monkeys after single intravenous and oral administrations of [14C]-ITF-296. Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):239-50. PubMed PMID: 9725488. 7: Monzani MV, Coltro G, Jiritano L, Sala A. Simultaneous determination of ITF 296 and two metabolites in plasma by a validated HPLC method. Boll Chim Farm. 1997 Apr;136(4):382-8. PubMed PMID: 9281893. 8: Duncker DJ, Mizrahi J, Bache RJ. Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries. J Cardiovasc Pharmacol. 1995 May;25(5):823-32. PubMed PMID: 7630161. 9: Sardina M, Love R, Mizrahi J, Monzani V, Bianchini C. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S72-9. PubMed PMID: 8839230. 10: Donà G, Giuliani P, Cremonesi P, Passaro A, Stella P, Tursi F, Mizrahi J. Mechanism of ITF 296-induced vasorelaxation compared to nitroglycerin and isosorbide dinitrate: relationship between relaxation of rabbit aorta and tissue cGMP. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S59-66. PubMed PMID: 8839228. 11: Rossoni G, Berti F, Bernareggi M, Villa L, Agozzino S, Cereda R, Giuliani P, Mizrahi J. Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemia. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S44-52. PubMed PMID: 8839226. 12: Trivella MG, Barsotti G, Cereda R, Chiaverini F, Gromo G, L'Abbate A, Magnozzi D, Mizrahi J, Pelosi G, Taddei L, et al. The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosis. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S31-6. PubMed PMID: 8839224. 13: Fink B, Cereda R, Bassenge E. Effect of ITF 296 on total effective vascular compliance in the anesthetized dog under autonomic blockade. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S21-25. PubMed PMID: 8839222. 14: Ghaleh B, Dubois-Randé JL, Hittinger L, Berdeaux A, Giudicelli JF. ITF 296, a new endothelium-independent vasodilator: comparison with nitroglycerin and isosorbide dinitrate. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S6-12. PubMed PMID: 8839220. 15: Benedini F, Bertolini G, Cereda R, Donà G, Gromo G, Levi S, Mizrahi J, Sala A. New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-ones. J Med Chem. 1995 Jan 6;38(1):130-6. PubMed PMID: 7837224. 16: Sardina M, Warrington SJ, Boyce M, Johnston A, Bianchini C. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S80-90. PubMed PMID: 8839231. 17: Monzani MV, Coltro G, Jiritano L, Sala A. Pharmacokinetic profile of ITF 296 in rats and dogs. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S67-71. PubMed PMID: 8839229. 18: Desta B, Nakashima M, Vanhoutte PM, Boulanger CM. The nitrate ester ITF 296 relaxes isolated canine arteries and veins. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S53-8. PubMed PMID: 8839227. 19: Cereda R, Bergamaschi M, Agozzino S, Bravi F, Gromo G, Mascheroni G, Mizrahi J. Protective effect of the nitrate ester ITF 296 against methacholine-induced myocardial ischemia in the anesthetized rat. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S37-43. PubMed PMID: 8839225. 20: Bassenge E, Cereda R, Fink B. Effects of ITF 296 on epicardial coronary artery diameter during acute and long-term treatment in the conscious dog. J Cardiovasc Pharmacol. 1995;26 Suppl 4:S26-30. PubMed PMID: 8839223.